Skip to content

Post-chemotherapy Axillary Conservation Surgery in breast cancer

An open label, phase 3 randomized trial to evaluate the role of axillary conservation surgery in breast cancer patients post-neoadjuvant chemotherapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044461
Enrollment
2316
Registered
2022-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Only low axillary sampling OR sentinel node biopsy: Patients on the experimental arm would undergo low axillary sampling OR sentinel node biopsy instead of total axillary clearance as p

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Histopathologically proven Breast Cancer 2 All patients with non metastatic breast cancer cT1 to 4 cN0 to 2 before beginning neoadjuvant chemotherapy 3 Post NACT cN0 4 Patient voluntarily willing to give consent for study

Exclusion criteria

Exclusion criteria: 1 Inflammatory breast cancer 2 Recurrent disease 3 Pregnant and lactating patients 4 Metastatic disease (including oligometastasis) 5 Pre-chemotherapy cN3 status (supraclavicular lymph node involvement and or internal mammary lymph node involvement) 6 Women who have received prior chemo or hormonal therapy for breast cancer or co-existing or previously treated non breast malignancy (such as hematolymphoid or ovarian cancer

Design outcomes

Primary

MeasureTime frame
To show the non-inferiority of DFS between axillary conservative surgery (defined further as low axillary sampling or equivalent sentinel node biopsy procedure) as compared to complete axillary lymph node dissection in patients who are rendered node negative clinically after neoadjuvant chemotherapyTimepoint: At each follow up visit till completion of 5 years

Secondary

MeasureTime frame
To show a reduction in arm and shoulder morbidity with low axillary sampling To assess the difference between the rate of regional nodal recurrence rate, local recurrence, distal recurrence To compare the overall survival in the two groups To assess the RT dose delivered to axilla in both arms by proper dosimetric studiesTimepoint: Assessment will be done at each followup visit till completion of 5 years of treatment completion

Countries

India

Contacts

Public ContactDr Shalaka P Joshi

Tata Memorial Hospital

drjoshishalaka@gmail.com02224177198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026